Recent improvements in enzyme-linked immunosorbent assays based on nanomaterials

Zhao, Qian; Dai, Lu; Zhang, Guangyin; Zhang, Dong; Shi, Xingbo

doi:10.1016/j.talanta.2020.121722

Cited by 117 publications

(45 citation statements)

References 172 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been widely used for clinical diagnosis, environmental monitoring, and food safety . However, it still has some drawbacks, such as dependence on enzymes, − moderate sensitivity, , single signal readout, and interference of colored samples . The boom of nanotechnology has yielded exciting developments in the design of improved ELISAs based on nanomaterials. , Ongoing attempts that have been carried out to improve the performance of traditional ELISA include the following: (1) using nanomaterials as carriers for the enrichment of enzymes due to their large surface-to-volume ratio; , (2) using nanomaterials as signal transducers to construct plasmonic ELISAs; , and (3) employing nanoparticles as a substitute for natural enzymes because of their intrinsic peroxidase-like activity (nanozymes). − These strategies have significantly improved the detection sensitivity and effectively circumvented inherent defects of the enzyme.…”

Section: Introductionmentioning

confidence: 99%

“…It has been widely used for clinical diagnosis, 1 environmental monitoring, and food safety. 2 However, it still has some drawbacks, such as dependence on enzymes, 3−5 moderate sensitivity, 6,7 single signal readout, 8 and interference of colored samples. 9 The boom of nanotechnology has yielded exciting developments in the design of improved ELISAs based on nanomaterials.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

An In Situ Generated Prussian Blue Nanoparticle-Mediated Multimode Nanozyme-Linked Immunosorbent Assay for the Detection of Aflatoxin B1

Dai

Jiang

Zhang

et al. 2021

ACS Appl. Mater. Interfaces

Self Cite

View full text Add to dashboard Cite

This work aims to develop a novel multimode (photothermal/colorimetric/fluorescent) nanozyme-linked immunosorbent assay (NLISA) based on the in situ generation of Prussian blue nanoparticles (PBNPs) on the surface of magnetic nanoparticles (MNPs). Being considered the most toxic among the mycotoxins, aflatoxin B1 (AFB1) was chosen as the proof-of-concept target. In this strategy, MNPs, on which an AFB1 aptamer was previously assembled via streptavidin-biotin linkage, are anchored to 96-well plates by AFB1 and antibody. In the presence of HCl and K4Fe(CN)6, PBNPs formed in situ on the MNP surface, thereby achieving photothermal and colorimetric signal readout due to their photothermal effect and intrinsic peroxidase-like activity. Based on fluorescence quenching by MNPs, Cy5 fluorescence was recovered by the in situ generation of PBNPs to facilitate ultrasensitive fluorescence detection. Photothermal and colorimetric signals allow portable/visual point-of-care testing, and fluorescent signals enable accurate determination with a detection limit of 0.54 fg/mL, which is 6333 and 28 times lower than those of photothermal and colorimetric analyses, respectively. We expect that this proposed multimode NLISA can not only reduce the false-positive/negative rates through the multisignal crossdetection in AFB1 monitoring but also provide a universal way of sophisticated instrumentation-free, easy-to-use, cost-effective, and highly sensitive detection of other food hazards.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

An In Situ Generated Prussian Blue Nanoparticle-Mediated Multimode Nanozyme-Linked Immunosorbent Assay for the Detection of Aflatoxin B1

Dai

Jiang

Zhang

et al. 2021

ACS Appl. Mater. Interfaces

Self Cite

View full text Add to dashboard Cite

show abstract

“…A major limitation of traditional serological assay techniques, such as ELISA, is their narrow dynamic range and low throughput, which do not allow for unequivocal and unambiguous interpretation of results. 34 This would be a particular issue for SARS‐CoV‐2 detection because of potential for significant cross‐reactivity to other seasonal coronavirus infections. 22 , 35 Specificity can be augmented by evaluating humoral immunity to more than one viral‐associated antigen at a time by using multiplexing.…”

Section: Discussionmentioning

confidence: 99%

Validation and performance of a multiplex serology assay to quantify antibody responses following SARS‐CoV‐2 infection or vaccination

et al. 2022

View full text Add to dashboard Cite

Objectives. Robust, quantitative serology assays are required to accurately measure antibody levels following vaccination and natural infection. We present validation of a quantitative, multiplex, SARS-CoV-2, electrochemiluminescent (ECL) serology assay; show correlation with two established SARS-CoV-2 immunoassays; and present calibration results for two SARS-CoV-2 reference standards. Methods. Precision, dilutional linearity, ruggedness, analytical sensitivity and specificity were evaluated. Clinical sensitivity and specificity were assessed using serum from prepandemic and SARS-CoV-2 polymerase chain reaction (PCR)positive patient samples. Assay concordance to the established Roche Elecsys ® Anti-SARS-CoV-2 immunoassay and a live-virus microneutralisation (MN) assay was evaluated. Results. Standard curves demonstrated the assay can quantify SARS-CoV-2 antibody levels over a broad range. Assay precision (10.2−15.1% variability), dilutional linearity (≤ 1.16-fold bias per 10-fold increase in dilution), ruggedness (0.89−1.18 overall fold difference), relative accuracy (107−118%) and robust selectivity (102−104%) were demonstrated. Analytical sensitivity was 7, 13 and 7 arbitrary units mL −1 for SARS-CoV-2 spike (S), receptor-binding domain (RBD) and nucleocapsid (N) antigens, respectively. For all antigens, analytical specificity was > 90% and clinical specificity was 99.0%. Clinical sensitivities for S, RBD and N antigens were 100%, 98.8% and 84.9%, respectively. Comparison with the Elecsys ® immunoassay showed ≥ 87.7% agreement and linear correlation (Pearson r of 0.85, P < 0.0001) relative to the MN assay. Conversion factors for the WHO International Standard and Meso Scale Discovery ® Reference Standard are presented. Conclusions. The multiplex SARS-CoV-2 ECL serology assay is suitable for efficient, reproducible measurement of antibodies to SARS-CoV-2 antigens in human sera, supporting its use in clinical trials and seroepidemiology studies.

show abstract

“…However, the enzymatic signal amplification confronts low sensitivity because of the limited number of enzymes involved in the recognition event (generally one enzyme molecule in each event). The utilization of polymeric conjugates and nanomaterials for loading of numerous enzymes has proven to be an effective strategy to enhance the sensitivity [3,4]. However, some disadvantages, such as complicated preparation procedure, high cost, low stability and strict storage condition, seriously hamper the applications of enzyme labels [5].…”

Section: Introductionmentioning

confidence: 99%

Fluorescent Immunoassay with a Copper Polymer as the Signal Label for Catalytic Oxidation of O-Phenylenediamine

et al. 2022

View full text Add to dashboard Cite

This work suggested that Cu2+ ion coordinated by the peptide with a histidine (His or H) residue in the first position from the free N-terminal reveals oxidase-mimicking activity. A biotinylated polymer was prepared by modifying His residues on the side chain amino groups of lysine residues (denoted as KH) to chelate multiple Cu2+ ions. The resulting biotin-poly-(KH-Cu)20 polymer with multiple catalytic sites was employed as the signal label for immunoassay. Prostate specific antigen (PSA) was determined as the model target. The captured biotin-poly-(KH-Cu)20 polymer could catalyze the oxidation of o-phenylenediamine (OPD) to produce fluorescent 2,3-diaminophenazine (OPDox). The signal was proportional to PSA concentration from 0.01 to 2 ng/mL, and the detection limit was found to be eight pg/mL. The high sensitivity of the method enabled the assays of PSA in real serum samples. The work should be valuable for the design of novel biosensors for clinical diagnosis.

show abstract

Recent improvements in enzyme-linked immunosorbent assays based on nanomaterials

Cited by 117 publications

References 172 publications

An In Situ Generated Prussian Blue Nanoparticle-Mediated Multimode Nanozyme-Linked Immunosorbent Assay for the Detection of Aflatoxin B1

An In Situ Generated Prussian Blue Nanoparticle-Mediated Multimode Nanozyme-Linked Immunosorbent Assay for the Detection of Aflatoxin B1

Validation and performance of a multiplex serology assay to quantify antibody responses following SARS‐CoV‐2 infection or vaccination

Fluorescent Immunoassay with a Copper Polymer as the Signal Label for Catalytic Oxidation of O-Phenylenediamine

Contact Info

Product

Resources

About